Claims for Patent: 11,007,198

Summary for Patent: 11,007,198

Title:	ErbB/BTK inhibitors
Abstract:	Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.
Inventor(s):	Zhengtao LI, Hao Zou, Wei Zhu, Changmao Shen, Rumin WANG, Wengeng LIU, Xiang Chen, Honchung Tsui, Zhenfan YANG, Xiaolin Zhang
Assignee:	Dizal Jiangsu Pharmaceutical Co Ltd
Application Number:	US16/910,208
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,007,198
Patent Claims:	1. A compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof, wherein, A1 is CH; A2 and A5 are CH, A3 and A4 are each independently CH substituted by R, R1 and R2 taken together with the nitrogen atom to which they are bound to form a monocyclic ring of which is optionally mono-substituted by —NRaRb, wherein, Ra and Rb are each independently selected from hydrogen or C1-12 alkyl; R3 is H; R4 and R5 are each independently unsubstituted C1-6 alkyl, R6 is hydrogen, R7 is C1-12 alkyl, n is 2; each R is independently halogen. 2. The compound of claim 1, which is selected from the group consisting of 3. A pharmaceutical composition comprising one or more compounds of Formula (I), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof according to claim Las a first active ingredient, and a pharmaceutically acceptable diluent, excipient or carrier. 4. A composition comprising a compound of claim 1, in combination with a second therapeutic agent. 5. The composition of claim 4, wherein the second therapeutic agent is an anti-tumour agent.